Four routes remain when a plan will not pay: buy the branded product at the manufacturer’s published self-pay price, move to a medication the plan does cover, pursue approval under the sleep apnea indication where it applies, or obtain compounded tirzepatide through a supervised practice. The right one follows from the reason the plan refused, not from the insurer’s name.
The reason for the refusal narrows the options fast
Two situations feel identical at the pharmacy register and have almost nothing in common. In the first, the benefit itself carves out anti-obesity medication as a category, usually because a self-funded employer chose a design that omits it. No amount of clinical documentation reverses that. In the second, the category exists and one condition was unmet, such as an authorization that was never filed or a step requirement.
Sorting this out takes one document. The plan’s summary of benefits states whether weight management drugs are a covered category at all, and the drug list attached to the member ID states whether this particular product sits on it. Both are keyed to a specific plan, which is why generic answers about a national insurer rarely hold. Where the category is genuinely excluded, spending weeks on paperwork is a poor trade and the cash routes below are the real decision.
The manufacturer channel now sets the reference price
Eli Lilly sells Zepbound single-dose vials directly to people paying cash through its own pharmacy channel, and Novo Nordisk runs a parallel self-pay route for Wegovy. Those published figures are the number every other option should be measured against, because they removed the era in which an uninsured buyer faced a four-figure monthly bill and no alternative.
Read the conditions rather than the headline. Self-pay prices differ by dose and by presentation, refill timing rules apply, and the vial format is priced differently from the autoinjector pen. A quote for the 2.5 mg starting dose is not the price at a 10 mg or 15 mg maintenance dose, and the maintenance figure is the one that decides whether treatment lasts past the fourth month.
The manufacturer number is easier to judge with a few comparison points beside it. Cash-pay telehealth providers post their own monthly prices, and reading a couple against the Lilly quote shows how much of a figure is medication and how much is the visit wrapped around it. Providers such as HealthRX, Henry Meds and Ro each publish a Zepbound pricing page, and the number to record from each is the one at the maintenance dose rather than the starting one.
Savings cards answer a different question
Manufacturer copay cards get read as cash discounts and are not. Most assume the person already holds commercial insurance that covers the drug, with the card trimming the copay that remains. Someone whose plan excludes the whole category usually does not qualify for the largest advertised reduction. Anyone with Medicare, Medicaid or TRICARE is generally shut out of commercial copay assistance by the terms of the offer itself.
A second approved indication can reopen the covered route
Zepbound is approved for weight reduction and separately for moderate to severe obstructive sleep apnea in adults with obesity. That matters commercially, because plan exclusions and the Medicare drug benefit are written around the use rather than the molecule. A person with a documented sleep study and a qualifying diagnosis may have a covered path that a person seeking the same drug purely for weight loss does not. The supporting trial, SURMOUNT-OSA, tested tirzepatide in adults with obesity and obstructive sleep apnea and reported reductions in apnea-hypopnea index against placebo.
This is worth checking before paying cash for a year. It costs one conversation with the prescribing office and a look at whether an existing sleep study is on file.
What the four routes actually compare on
| Route | What sets the price | Best fit | Main catch |
|---|---|---|---|
| Manufacturer self-pay | Published cash price by dose and vial | Anyone paying out of pocket | Price rises with maintenance dose |
| Copay savings card | Copay left after the plan pays | Commercially insured, drug covered | Government coverage disqualifies |
| Covered substitute | Formulary tier and deductible | Plans covering some obesity drugs | Step therapy may come first |
| Sleep apnea pathway | Same benefit, different indication | Documented moderate to severe OSA | Requires a sleep study on file |
| Compounded tirzepatide | Pharmacy and practice pricing | Category excluded outright | Not an FDA-approved product |
Compounded medication is a different product class
Compounded tirzepatide and semaglutide are prepared by compounding pharmacies rather than manufactured under an approved application, so the agency does not review them for safety, effectiveness or manufacturing quality the way it reviews the branded products. The FDA has also removed both molecules from its drug shortage list, which narrowed the legal room that large scale compounding of near copies had relied on. Anyone choosing this route should treat the regulatory position as changeable.
Pricing is the reason people look. Supervised telehealth practices publish flat monthly cash figures that include the visit and the medication, and the field includes Hims and Hers, Ro, LifeMD and FormBlends among others. The questions that separate them are whether a licensed clinician actually reviews the case, which pharmacy fills the order, whether the price holds as the dose increases, and how cancellation works.
Price the year, not the month
The decision that matters is the twelve month figure at a maintenance dose, not the introductory number. Dose escalation raises the cost of most routes, and stopping is not a neutral outcome. Withdrawal data for this drug class show weight regain after discontinuation, and continued treatment is what preserved the result in maintenance trials. A route that is affordable in month one and abandoned in month six converts spending into no lasting benefit.
Writing the arithmetic down is unglamorous and effective. List the monthly price at the expected maintenance dose for each route that is genuinely open, multiply by twelve, and compare that against what a successful authorization would cost over the same period. The cheapest month and the cheapest year are frequently different answers.
Frequently asked questions
Does paying cash forfeit any later attempt at coverage?
No. Buying out of pocket does not close the door on an authorization later, and a documented response to treatment sometimes strengthens a subsequent request. What paying cash does not do is generate a claim history with the plan, so the record of treatment lives with the prescriber rather than the insurer.
Can a discount pharmacy coupon be used on Zepbound?
Discount card networks negotiate on generics and older brands, and they have little room on a single-source brand drug with no generic equivalent. The manufacturer’s own self-pay channel is normally the better comparison point. Prices at independent pharmacies vary, so it is worth calling more than one before assuming a figure.
Is switching to a covered alternative a real option?
Sometimes. Plans that exclude one weight management drug often cover another, and head-to-head evidence for these agents differs by molecule and dose. A prescriber can judge whether an alternative suits the clinical picture. Where the entire category is excluded, no substitute inside it will be covered either.
What happens to cash spending if coverage starts mid-year?
Out-of-pocket payments made without a claim generally do not count toward a deductible or an out-of-pocket maximum. Submitting a paper claim after the fact is possible on some plans and is usually rejected on plans that exclude the category. Checking before spending several months of cash is the useful order.
How much does the FDA shortage delisting change things?
It changes the basis on which compounders may prepare copies of an approved drug. State-licensed pharmacies continue to compound in defined circumstances, and personalized formulations are treated differently from mass produced copies. The practical effect is that availability through any given provider can change without notice.
